Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Caly, Chien"'
Autor:
Arvind Dasari, Erika P. Hamilton, Gerald S. Falchook, Judy S. Wang, Daneng Li, Max W. Sung, Caly Chien, Shivani Nanda, Christopher Tucci, Marjo Hahka-Kemppinen, Andrew Scott Paulson
Publikováno v:
Investigational New Drugs.
Surufatinib, is a potent inhibitor of vascular endothelial growth factor receptors 1–3; fibroblast growth factor receptor-1; colony-stimulating factor 1 receptor. This Phase 1/1b escalation/expansion study in US patients with solid tumors evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddcb9a02f4a998a162d10207c8e45627
https://doi.org/10.1007/s10637-023-01359-2
https://doi.org/10.1007/s10637-023-01359-2
Autor:
Andreas Engert, Carla J. de Boer, Sonja Kotoulek, Regina Aquino, Shobha Seetharam, Caly Chien, Max S. Topp, Vincent Ribrag, Franck Morschhauser, Bastian von Tresckow
Purpose: This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase as treatment for relapsed or refractory classical Hodgkin lymphoma (cHL).Experimental Design: Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49c7de90b064ae02712561e366675b9f
https://doi.org/10.1158/1078-0432.c.6522986.v1
https://doi.org/10.1158/1078-0432.c.6522986.v1
Autor:
Fred Saad, Juhui J. Jiao, Charlene Abrams, Caly Chien, Peter Hellemans, Margaret K. Yu, Terence W. Friedlander, Gerhardt Attard, Maja J.A. de Jonge, Ronald de Wit, Kim N. Chi, Edwin M. Posadas
Duration of treatment exposure and PSA response since start of therapy for patients receiving systemic therapy with an AR signaling inhibitor prior to study entry
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af6a97e106bd3776cad7573d26bf9aa2
https://doi.org/10.1158/1078-0432.22475339.v1
https://doi.org/10.1158/1078-0432.22475339.v1
Autor:
Andreas Engert, Carla J. de Boer, Sonja Kotoulek, Regina Aquino, Shobha Seetharam, Caly Chien, Max S. Topp, Vincent Ribrag, Franck Morschhauser, Bastian von Tresckow
Supplementary Table 1: Extent of Exposure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a9f60b8285041359ca86445c83a175f
https://doi.org/10.1158/1078-0432.22455317.v1
https://doi.org/10.1158/1078-0432.22455317.v1
Autor:
Fred Saad, Juhui J. Jiao, Charlene Abrams, Caly Chien, Peter Hellemans, Margaret K. Yu, Terence W. Friedlander, Gerhardt Attard, Maja J.A. de Jonge, Ronald de Wit, Kim N. Chi, Edwin M. Posadas
Purpose:Apalutamide is a next-generation androgen receptor (AR) inhibitor approved for patients with nonmetastatic castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer. We evaluated the pharmacokinetics, saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3711af714fc0d64f3b44ad92c52c676
https://doi.org/10.1158/1078-0432.c.6529049.v1
https://doi.org/10.1158/1078-0432.c.6529049.v1
Autor:
Fred Saad, Juhui J. Jiao, Charlene Abrams, Caly Chien, Peter Hellemans, Margaret K. Yu, Terence W. Friedlander, Gerhardt Attard, Maja J.A. de Jonge, Ronald de Wit, Kim N. Chi, Edwin M. Posadas
Figure legends for Figure S1 and Figure S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::312adf9420dc6e1c57832de0fb1cd84f
https://doi.org/10.1158/1078-0432.22475351.v1
https://doi.org/10.1158/1078-0432.22475351.v1
Autor:
Fred Saad, Juhui J. Jiao, Charlene Abrams, Caly Chien, Peter Hellemans, Margaret K. Yu, Terence W. Friedlander, Gerhardt Attard, Maja J.A. de Jonge, Ronald de Wit, Kim N. Chi, Edwin M. Posadas
Confirmed PSA response (as change from baseline) at any time for patients who received no prior therapy with AA-P or ENZ and patients who received therapy with AA-P only, ENZ only, or both AA-P and ENZ prior to study entry. Postbaseline PSA measureme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fe6f7f3fddf615700ffb3c7c26baf4f
https://doi.org/10.1158/1078-0432.22475345.v1
https://doi.org/10.1158/1078-0432.22475345.v1
Autor:
Juan Jose Perez-Ruixo, Eric J. Small, David Olmos, Daniele Ouellet, Margaret K. Yu, Matthew R. Smith, Paul N. Mainwaring, Carlos Perez-Ruixo, Hiroji Uemura, Oliver Ackaert, Caly Chien, Ji Youl Lee
Publikováno v:
Clinical Cancer Research. 26:4460-4467
Purpose: To evaluate the relationship between exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, and selected clinical efficacy and safety parameters in men with high-risk nonmetastatic castration-resistant prostate cancer. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba76624b4291c116cd50b095b87ff61d
https://doi.org/10.1158/1078-0432.ccr-20-1041
https://doi.org/10.1158/1078-0432.ccr-20-1041
Autor:
James Jiao, Iurie Bulat, Caly Chien, Anna Mitselos, Danielle Armas, Peter Hellemans, Joan Carles, Peter Ward, Ignacio Duran
Publikováno v:
Clinical Pharmacokinetics. 59:1135-1148
Two phase I studies assessed the drug–drug interaction potential of apalutamide as a substrate and perpetrator. Study A randomized 45 healthy men to single-dose apalutamide 240 mg alone or with strong inhibitors of cytochrome P450 (CYP)3A4 (itracon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c46c05ed5a1ccb9bb23eca13cec96541
https://doi.org/10.1007/s40262-020-00882-2
https://doi.org/10.1007/s40262-020-00882-2
Autor:
Juhui J. Jiao, Peter Hellemans, Gerhardt Attard, Kim N. Chi, Fred Saad, Caly Chien, Margaret K. Yu, Maja J.A. de Jonge, Terence W. Friedlander, Charlene Connelly Abrams, Edwin M. Posadas, Ronald de Wit
Publikováno v:
Clinical Cancer Research, 26(14), 3517-3524. American Association for Cancer Research Inc.
Purpose: Apalutamide is a next-generation androgen receptor (AR) inhibitor approved for patients with nonmetastatic castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer. We evaluated the pharmacokinetics, sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8df254122b3abc1d8c6f30e8e5eadd7
https://doi.org/10.1158/1078-0432.ccr-19-3402
https://doi.org/10.1158/1078-0432.ccr-19-3402